The Mumbai headquartered contract research and manufacturing services (CRAMS) major told the DNA website that pharmaceutical industry cost cutting in the wake of the economic downturn will continue to be the key growth driver.
It went on to predict that operations in Japan, a market which Dishman only entered last year, will also aid growth over the coming financial year and forecast that they will contribute revenues of $10m by March next year.
Dishman also expects its US business to grow significantly, and forecast that operations in the country will generate $10-15m by 2012.